Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Veterans Affairs Cooperative Studies Program no. 424

William E. Boden, Robert A. O'Rourke, Koon K. Teo, Pamela M. Hartigan, David J. Maron, William Kostuk, Merril Knudtson, Marcin Dada, Paul Casperson, Crystal L. Harris, John A. Spertus, Leslee Shaw, Bernard R. Chaitman, G. B.John Mancini, Daniel S. Berman, William S. Weintraub

Research output: Contribution to journalArticlepeer-review

79 Scopus citations

Abstract

Background: Major improvements in medical therapy and percutaneous coronary intervention (PCI) for coronary heart disease have occurred during the past decade, but no randomized trial has compared these 2 strategies for the "hard" clinical end points of death or myocardial infarction nor have earlier studies incorporated the use of coronary stents and aggressive multifaceted medical therapy during long-term follow-up. Methods: The COURAGE trial is a multicenter study of patients with documented myocardial ischemia and angiographically confirmed single or multivessel coronary artery disease who are randomized to a strategy of PCI plus intensive medical therapy or intensive medical therapy alone. Medical therapy in both groups is guideline-driven and includes: aspirin, clopidogrel, simvastatin (low-density lipoprotein cholesterol target 60-85 mg/dL), long-acting metoprolol and/or amlodipine, lisinopril or losartan, and long-acting nitrates, as well as lifestyle interventions. The primary end point is a composite of all-cause mortality or acute myocardial infarction, and there will be 85% power to detect an absolute 4.6% (relative 22%) difference between strategies. The principal hypothesis is that PCI plus aggressive medical therapy (projected event rate 16.4%) will be superior to aggressive medical therapy alone (projected event rate 21%) during a 2.5- to 7-year (median of 5 years) follow-up. Conclusions: COURAGE is the largest prospective randomized trial of PCI versus intensive medical therapy to date and will define the incremental benefits of PCI in the setting of contemporary optimal medical therapy for chronic coronary heart disease. A total of 2287 patients have been enrolled, and follow-up will conclude in June 2006.

Original languageEnglish
Pages (from-to)1173-1179
Number of pages7
JournalAmerican Heart Journal
Volume151
Issue number6
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Dive into the research topics of 'Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Veterans Affairs Cooperative Studies Program no. 424'. Together they form a unique fingerprint.

Cite this